Clinical Cancer Research, Vol 4, Issue 3 683-691, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II

AA Adjei, M Charron, EK Rowinsky, PA Svingen, J Miller, JM Reid, J Sebolt-Leopold, MM Ames and SH Kaufmann
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.

Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor cells, cytotoxicity in noncycling and hypoxic cells, and promising antitumor activity in Phase I clinical trials. In the present study, the effect of PA on topoisomerase (topo) activity was evaluated using yeast strains lacking functional topo I or II, mammalian cell nuclear extracts, purified samples of mammalian topo I and topo II, and intact mammalian tissue culture cells. Clonogenic assays revealed that PA cytotoxicity in yeast strains was unaffected by selective loss of topo I or topo II activity. On the other hand, enzyme assays revealed that 2-4 microM PA abolished the catalytic activity of both topo I and topo II in vitro. In contrast to topotecan and etoposide, PA did not stabilize covalent topo-DNA complexes. Instead, PA inhibited topotecan-induced stabilization of covalent topo I-DNA complexes and etoposide-induced stabilization of topo II-DNA complexes in vitro and in intact cells. Consistent with these results, colony-forming assays indicated that short-term PA exposure inhibited the cytotoxicity of topotecan and etoposide, whereas prolonged PA exposure was itself toxic to these cells. Accumulation studies revealed that PA was concentrated as much as 250-fold in drug-treated cells, resulting in intranuclear concentrations that far exceeded those required to inhibit topo I and topo II. Collectively, these results not only suggest that PA can target both topo I and topo II at clinically achievable concentrations but also indicate that its mechanism is distinct from topo I and topo II poisons presently licensed for clinical use.

This article has been cited by other articles:

				V. A. Rao, K. Agama, S. Holbeck, and Y. Pommier Batracylin (NSC 320846), a Dual Inhibitor of DNA Topoisomerases I and II Induces Histone {gamma}-H2AX as a Biomarker of DNA Damage Cancer Res., October 15, 2007; 67(20): 9971 - 9979. [Abstract] [Full Text] [PDF]

				M. K. Ozvaran, X. X. Cao, S. D. Miller, B. A. Monia, W. K. Hong, and W. R. Smythe Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma Mol. Cancer Ther., May 1, 2004; 3(5): 545 - 550. [Abstract] [Full Text] [PDF]

				J. M. Reid, D. L. Walker, J. K. Miller, L. M. Benson, A. J. Tomlinson, S. Naylor, A. L. Blajeski, P. M. LoRusso, and M. M. Ames The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes Clin. Cancer Res., February 15, 2004; 10(4): 1471 - 1480. [Abstract] [Full Text] [PDF]

				Y. Hu, A. Krishan, W. Nie, K. S. Sridhar, L. D. Mayer, and M. Bally Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells Clin. Cancer Res., February 1, 2004; 10(3): 1160 - 1169. [Abstract] [Full Text] [PDF]

				N. Keshelava, D. Tsao-Wei, and C. P. Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 Clin. Cancer Res., August 1, 2003; 9(9): 3492 - 3502. [Abstract] [Full Text] [PDF]

				J. L. Grem, N. Harold, B. Keith, A. P. Chen, V. Kao, C. H. Takimoto, J. M. Hamilton, J. Pang, M. Pace, G. B. Jasser, et al. A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients Clin. Cancer Res., July 1, 2002; 8(7): 2149 - 2156. [Abstract] [Full Text] [PDF]

				S. I. Khan, A. C. Nimrod, M. Mehrpooya, J. L. Nitiss, L. A. Walker, and A. M. Clark Antifungal Activity of Eupolauridine and Its Action on DNA Topoisomerases Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1785 - 1792. [Abstract] [Full Text] [PDF]

				A. A. Adjei, J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines Clin. Cancer Res., May 1, 2001; 7(5): 1438 - 1445. [Abstract] [Full Text]

				R van Gijn, R. Lendfers, J. Schellens, A Bult, and J. Beijnen Dual topoisomerase I/II inhibitors Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 92 - 108. [Abstract] [PDF]

				K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann Flavopiridol Binds to Duplex DNA Cancer Res., May 1, 2000; 60(9): 2419 - 2428. [Abstract] [Full Text]